Single-use TFF offers the greatest savings in clinical and contract manufacturing, where the scale is low and changeovers are frequent.
Mark Perreault
Advertisement
Mark Perreault is the director of membrane application development for TangenX technology at Novasep
Articles by Mark Perreault
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
2
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
3
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5